Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?

• DOI: 10.1017/s0033291717003774
• Publication Date: 2018-01-14T11:31:01Z
• Authors: Alejandro Ballest...; Ana M. Sánchez-To...; Jose M. López-Ilu...; Bibiana Cabrera; Antonio Lobo; Ana M. González-P...; Covadonga Díaz-Ca...; Iluminada Corripio; Eduard Vieta; Elena de la Serna; Julio Bobes; Judith Usall; Fernando Contreras; Ruth Lorente-Omeñaca; Gisela Mezquida; Miguel Bernardo; Manuel J. Cuesta
• Keywords: cognition; Adult; Male; Intelligence; Anticholinergic; Cholinergic Antagonists; antipsychotics; Young Adult; 03 medical and health sciences; Cross-Sectional Studies; 0302 clinical medicine; Psychotic Disorders; premorbid intellectual quotient; first episode psychosis; Humans; Cognitive Dysfunction; Female; Antipsychotic Agents

Abstract Background Cognitive deficits are a core feature of early stages in schizophrenia. However, the extent to which antipsychotic (AP) have deleterious effect on cognitive performance remains under debate. We aim investigate whether anticholinergic loadings and dose AP drugs first episode psychosis (FEP) advanced phase remission associated with impairment differences between premorbid intellectual quotient (IQ) subgroups. Methods Two hundred sixty-six patients participated. The primary outcomes were dimensions, dopaminergic/anticholinergic load [in chlorpromazine equivalents (Eq-CPZ) Anticholinergic Risk Scale (ARS), respectively]. Results Impairments processing speed, verbal memory global cognition significantly high Eq-CPZ ARS score. Moreover, this was higher low IQ subgroup. Conclusions Clinicians should be aware potential FEP, particularly lower patients.